Venn Life Sciences Holdings PLC Appointment of Non Executive Director (5034K)

TIDMVENN

RNS Number : 5034K

Venn Life Sciences Holdings PLC

22 September 2016

22 September 2016

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Appointment of Non-Executive Director

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Mary Sheahan as a Non-Executive Director ('NED') to the Board with immediate effect.

Mary Blake Sheahan, aged 44, is a dedicated senior leader with over 20 years' experience, at Executive Committee level of a multinational publicly listed biopharmaceutical company. Mary's most recent role was as Senior Vice President of Global Integration and Country Manager for Ireland with Perrigo Company plc, a NYSE-listed, $13 billion market cap leading global healthcare supplier. In this role, she was responsible for the successful integration of a $4.5bn acquisition of a leading European OTC Healthcare Company with operations in 35 countries.

Prior to this, Mary was Executive Vice President and Group Head of HR, IT, Facilities & Portfolio Assessment Management at Elan Corporation plc prior to its merger with Perrigo in 2013. Mary is a qualified chartered accountant having trained with KPMG.

Tony Richardson, Chief Executive Officer of Venn said: "Mary will be a great addition to the Board in a time of great progress and change at Venn. She has a proven track record of setting direction, strategic decision-making and delivering results in complex and challenging situations, across a range of disciplines including finance, strategy and commercial functions. She will add considerable value to our team.

Mary has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM rules and the ESM Rules.

 
 Current directorships        Directorships or partnerships 
  or partnerships              in the last five years 
----------------------------  --------------------------------- 
 
 Madiba Consulting Limited 
  Elan Science Three Limited    Prothena Corporation, 
                                plc 
                                Perrigo Holdings Limited 
                                Perrigo Corporation Limited 
                                Janssen Alzheimer Immunotherapy 
                                Unlimited 
                                Perrigo Finance plc 
 
 

Mary does not hold any interests in ordinary shares of Venn.

Enquiries:

 
Venn Life Sciences Holdings 
 Plc 
Allan Wood, Chairman                                Tel: [phone] 
Tony Richardson, Chief Executive                      Tel: [phone] 
 Officer                                                           341 
 
Davy (Nominated Adviser, ESM 
 Adviser and Joint Broker) 
Fergal Meegan / Matthew de Vere                        Tel: [phone] 
 White (Corporate Finance)                                        6363 
Orla Bolger (Corporate Broking) 
 
Hybridan LLP (Co-Broker) 
Claire Louise Noyce                                Tel: [phone] 
                                                                  2341 
 
Walbrook PR Ltd                              Tel: [phone] 
                                              or [e-mail] 
Paul McManus                                          Mob: [phone] 
                                                               541 893 
Lianne Cawthorne                                      Mob: [phone] 
                                                               391 303 
 
 

About Venn Life Sciences:

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAKFLFLQKFFBBD

(END) Dow Jones Newswires

September 22, 2016 02:01 ET (06:01 GMT)